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DOI 10.1016/j.ccr.2010.04.028SUMMARYOverexpression of phosphatase of regenerating liver (PRL)-3 is associated with the progression of diverse
human cancers. We show that the overexpression of PRL-3 protein is not directly associated with its tran-
script levels, indicating the existence of an underlying posttranscriptional regulation. The 50 untranslanted
region (UTR) of PRL-3 mRNA possesses triple GCCCAG motifs capable of suppressing mRNA translation
through interaction with PolyC-RNA-binding protein 1 (PCBP1), which retards PRL-3 mRNA transcript incor-
poration into polyribosomes. Overexpression of PCBP1 inhibits PRL-3 expression and inactivates AKT,
whereas knockdown of PCBP1 causes upregulation of PRL-3 protein levels, activation of AKT, and promo-
tion of tumorigenesis. An inverse correlation between protein levels of PRL-3 and PCBP1 in human primary
cancers supports the clinical relevance.INTRODUCTION
Cancer metastasis is the major cause of cancer mortality.
Despite this, metastasis remains the most poorly understood
aspect of human malignancy (Hanahan and Weinberg, 2000).
Phosphorylation and dephosphorylation are major regulatory
events affecting the functional activities of diverse proteins that
modulate cellular processes leading to cancer progression.
Although considerable attention has centered on protein kinases
in cancer development, the role of protein phosphatases in
cancer remains an underexplored area.
The first phosphatase induced in regenerating liver (PRL-1)
was identified in 1994 (Diamond et al., 1994). Subsequently,Significance
Metastasis is the most malevolent aspect of cancer. Upregula
lating PRL-3 overexpression is poorly understood. Our identifi
tion reveals amolecular mechanism responsible for the overexp
PCBP1 and PRL-3 protein levels in several human cancers su
logical and clinical relevance. The axis of PCBP1 – PRL-3 – AK
finding of PCBP1 as a tumor suppressor is highly significant as
52 Cancer Cell 18, 52–62, July 13, 2010 ª2010 Elsevier Inc.we identified two more PRL-family members, PRL-2 and PRL-
3 (Zeng et al., 1998). Among the 107 human protein tyrosine
phosphatases (PTPs), PRL-1, PRL-2 and PRL-3 represent an
oncogenic subgroup of the PTP-family with a unique C-terminal
prenylation motif (Alonso et al., 2004). The three PRL-members
represent an intriguing group of proteins that have emerged as
potential biomarkers for assessing tumor aggressiveness and
useful therapeutic targets in a variety of cancers (Bessette
et al., 2008; Stephens et al., 2005).
Global gene expression profiling of metastatic colorectal
cancer (CRC) in comparison with primary cancers and normal
colorectal epithelium revealed that PRL-3 was the only gene
consistently overexpressed in all 18 metastatic colorectaltion of PRL-3 causes metastases, but the mechanism regu-
cation of PCBP1 as an upstream regulator of PRL-3 transla-
ression of PRL-3 in cancer. The inverse correlation between
ggests that PCBP1-mediated PRL-3 regulation is of physio-
T may be a pathway in controlling cancer progression. The
a similar mechanismmay be regulating other cancer genes.
Table 1. PRL-3 Protein Expression in Human Cancers
Types of Cancer PRL-3+/Total Samples PRL-3+ %
Colon 62/301 20.6%
Breast 22/173 12.7%
Lung 45/155 29.0%
Pancreas 42/126 33.3%
Squamous 26/69 37.7%
Prostate 5/53 9.4%
Brain 2/20 10.0%
Esophagus 5/18 27.8%
Stomach 3/18 16.7%
Cervix 3/15 20.0%
Bladder 3/14 21.4%
Liver 2/14 14.3%
Ovary 1/12 8.3%
Kidney 1/12 8.3%
Skin 3/8 37.5%
All cancer types 225/1008 in total 22.3% in average
The percentages of PRL-3-positive cancers as detected with immunohis-
tochemistry are summarized.
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PCBP1 Suppresses PRL-3cancers (Saha et al., 2001). The mRNA expression of PRL-3 was
elevated in nearly all metastatic lesions derived from CRCs,
regardless of the site of metastasis (Bardelli et al., 2003). Since
then, PRL-3 has attracted the most attention among the three
members. PRL-3, also known as PTP4A3, is a retroviral tagged
cancer gene (http://rtcgd.abcc.ncifcrf.gov/mm9/index.html).
PRL-3 expression is implicated in ovarian cancer growth (Polato
et al., 2005) and might also play a significant role in invasion and
metastasis of gastric carcinoma (Miskad et al., 2004). Overex-
pression of PRL-3 correlates negatively with the prognosis of
liver cancers (Peng et al., 2004). By northern hybridization anal-
ysis, PRL-3 mRNA was shown to be upregulated in almost all 27
human liver carcinoma samples examined as compared to
normal liver samples (Wu et al., 2004). The level of PRL-3 protein
in primary colorectal tumors has prognostic significance in pre-
dicting the development of liver and lung metastases (Kato
et al., 2004). PRL-3 expression was higher in bone marrow
(BM) plasma cells from multiple myeloma patients with newly
diagnosed monoclonal gammopathies than in plasma cells
from healthy donors (Fagerli et al., 2008). Critical dose-depen-
dent effects of PRL-3 expression in both positive and negative
regulation of cell-cycle progression were highlighted in a recent
report (Basak et al., 2008), which provided insight into PRL-3’s
role in cancer progression, emphasizing the importance of
proper modulation of PRL-3 protein levels to affect its role in
cell cycle regulation. PRL-3 expression might be coordinately
regulated at transcriptional-translational levels, and in a tempor-
ospatial-dependent manner.
Increasing evidence suggest that PRL-3 is likely a multitasking
phosphatase involved in multiple steps of cancer progression.
PRL-3 overexpression was sufficient to promote cell migration,
invasion, and metastasis (Zeng et al., 2003). PRL3 promotes
cell invasion and proliferation by the downregulation of Csk
leading to Src activation, which initiates a number of signal path-
ways culminating in the phosphorylation of ERK1/2, STAT3, and
p130Cas (Liang et al., 2007). PRL-3 downregulates PTEN expres-
sion and signals through PI3K to promote epithelial-mesen-
chymal transition (EMT) (Wang et al., 2007a). Endothelial cell
recruitment and new blood vessel formation both play central
roles in tumor progression and cancer metastasis. Importantly,
PRL-3 could initiate tumor angiogenesis by recruiting endothelial
cells in vitro and in vivo (Guo et al., 2006). Despite its multiple
tasks in triggering cancer metastasis, little is known about the
molecular mechanisms underlying the regulation of PRL-3
expression in physiological or pathological conditions.
Because an excess of PRL phosphatase activity is clearly
a key alteration contributing to the acquisition of metastatic
properties in tumor cells, understanding how PRL-3 is regulated
will be essential to its exploitation as a therapeutic target to
retard cancer progression. Here, we investigate the translational
regulation of PRL-3 by the poly(C)-binding protein 1 (PCBP1 also
known as hnRNPE1), which is a member of the hnRNP family of
RNA- and/or DNA-binding proteins (Makeyev and Liebhaber,
2002). PCBP1 is known to participate in the regulation of RNA
transcription, pre-mRNA processing, maturation, and mRNA
export. PCBP1 has been reported to play crucial roles in
a broad-spectrum of transcriptional and translational events
(Huo and Zhong, 2008), but its molecular mechanism in cancer
development and progression remains to be defined.RESULTS
PRL-3 Protein Is Upregulated in Many Types of Human
Cancer
To expand previous observations that upregulation of PRL-3
correlates with metastasis of human cancers, we used two
specific PRL-3 mouse monoclonal antibodies (mAbs) (clones
223 and 318) (Li et al., 2005) to analyze >1000 multiple human
cancer samples for PRL-3 protein expression by immunohisto-
chemistry (IHC). The percentages of PRL-3 positive cancer types
are summarized in Table 1. PRL-3 protein levels were elevated in
an average of 22.3% of cancer samples (n = 1008). Selected
images were shown in Figure 1A. With six human tissue samples
(five tumors and one normal), a full western blot with PRL-3 mAb
(clone 318) shows that PRL-3 protein is expressed in three tumor
samples (Figure 1B).
PRL-3 mRNA and Protein Levels Are Not Strictly
Correlated in Cancer Cell Lines
To study how PRL-3 expression is regulated, we analyzed its
expression in 12 cancer cell lines. The results showed that the
PRL-3 mRNA levels in these cell lines were comparable (Figures
2A and 2B). However, PRL-3 protein was only detected in
a subset of these cancer cell lines by using two different PRL-3
mAb detecting different epitopes (Figures 2C and 2D). These
results indicate that regulation of PRL-3 levels not only occurs
at the transcription level (Saha et al., 2001) but may also present
at the translational level.
GC-Rich Motifs in the 50 UTR of PRL-3 mRNA Negatively
Regulate the Luciferase Reporter
We searched the expressed sequence tags (EST) database and
found that PRL-3 mRNA has a relatively long 50 UTR (855 b) and
30 UTR (540 b) compared to its coding region (519 b) (Figure 3A,Cancer Cell 18, 52–62, July 13, 2010 ª2010 Elsevier Inc. 53
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Figure 1. PRL-3 Protein Is Overexpressed in Human Cancers
(A) PRL-3 mAbs (clone 223 and clone 318) were used to detect PRL-3 protein expression in multiple human cancer samples. PRL-3-positive signals (DAB chro-
mogen in brown) were mainly detected at the plasma membrane and the Golgi- or endosomal-like subcellular structures in the cytoplasm. Selected images of
PRL-3-positive cancer samples are shown. The scale bar represents100 mm.
(B) A full western blot using PRL-3 mAb (clone 318) showed that PRL-3 protein was expressed in three of five tumor samples. T, tumor; N, normal, Ts in red are
PRL-3-positive tumors.
Cancer Cell
PCBP1 Suppresses PRL-3the mRNA sequence provided in Figure S1A available online).
Given that PRL-3 mRNA and protein levels are not correlated
in cancer cell lines (Figure 2), we hypothesized that the 50 UTRFigure 2. PRL-3 mRNA and Protein Levels Are Not Strictly Corre-
lated in Cancer Cell Lines
(A and B) Total RNAswere extracted from 12 human cell lines and 1mouse cell
line-CT26*. The expression of PRL-3mRNAswas assayed by semiquantitative
RT-PCR using GAPDHmRNA as a control (A) or by Northern blot analysis with
18S rRNA as a loading control (B). Mouse PRL-3 mRNA (*) is smaller than
human PRL-3 mRNA.
(C and D) The levels of PRL-3 protein expression in the indicated cell lines
were assessed by immunoblot analysis with PRL-3 mAb (C) clone 223 or (D)
clone 318.
54 Cancer Cell 18, 52–62, July 13, 2010 ª2010 Elsevier Inc.(or the 30 UTR) of PRL-3mRNAmight harbor some cis-regulatory
elements affecting PRL-3 translation. We then linked 2.4 Kb of
the upstream genomic sequence (assumed to contain promoter
and enhancer sequences) of the PRL-3 gene to a series of 30 end
deletions of the 50 UTR, followed by the luciferase reporter to
make eight constructs (Figure 3B, a–h). The eight constructs
were then respectively transfected into the human colorectal
cancer cell line DLD-1, which expresses the PRL-3 mRNA but
not the protein (Figure 2, lane 3) making it a suitable system to
study the regulation of PRL-3 translation. Seven constructs
(Figure 3C, a–g) showed relatively low luciferase activities.
Importantly, when the 50-GCCCAG-30 sequence at position
+49 to +55 was deleted (Figure 3C, h), there was a robust
increase (5- to 6-fold) in luciferase activity. This was independent
of mRNA level as RT-PCR showed similar luciferase mRNA
abundance after normalizing to Renilla for all the eight constructs
(quantitative mRNA abundance shown in Figure S1B). Intrigu-
ingly, the same GC-motif was also found at two more positions
in the 50 UTR: +72 to +77, and +155 to +160 (Figure S1A, under-
lined sequences). This raised the question of whether the three
GC-motifs play an equal role in modulating PRL-3 repression
in a dose-dependent manner. We found that the translational
repression activity is not proportional to the copy numbers of
GC-motif as we did not see significant difference in luciferase
activities among constructs harboring with one, two, or three
GC-motifs (Figure 3C, a–g). A single GC-motif at position +49
to +55 was sufficient to suppress luciferase expression
(Figure 3C, g).
To confirm this was a general phenomenon, we again respec-
tively transfected the same eight constructs (Figure 3B, a–h) into
another human colorectal cancer cell line HCT-116 that
Cancer Cell
PCBP1 Suppresses PRL-3expresses both PRL-3 mRNA and protein (Figure 2C, lane 2).
Compared with construct g (1-GC-motif; Figure 3B), a 2.5-fold
induction of enzyme activity was observed for construct h (0-
GC-motif; Figure 3D) although RT-PCR showed the eight
constructs (Figure 3B, a–h) expressed similar levels of mRNA
in HCT-116 cells (quantitative mRNA abundance shown in
Figure S1C). The lesser induction (2.5-fold) in HCT-116 cells
compared to higher induction (5- to 6-fold) in DLD-1 cells indi-
cates that the degree of repression could be cell-type specific.
These results suggest that the GC-motif is at least partly respon-
sible for the translational repression of PRL-3 seen in DLD-1 and
to a lesser extent, in HCT-116 cells. To exclude the possibility
that deletion of putative cis-acting elements may affect mRNA
stability, we looked at the levels of luciferase mRNA in the pres-
ence of actinomycin D, which prevents the synthesis of new
mRNAs. By quantitative real-time RT-PCR (qRT-PCR), although
luciferase transcript levels for constructs a–h (see Figures S1D
and S1E) showed no major difference in both DLD-1 and HCT-
116 cells, a specific increase in luciferase activity was seen in
construct h (Figures S1F and S1G) in DLD-1 and HCT-116 cells.
The lack of correlation between mRNA levels and luciferase
activity among these eight constructs suggested that the
increase in luciferase activity was not due to changes in mRNA
stability. The above results illustrate that the 6-base GC-motif
negatively regulates translation.
GC-Rich Motifs in the 50UTR of PRL-3 mRNA Negatively
Regulate PRL-3 Protein Translation
To investigate whether the coding sequence of PRL-3 mRNA is
also subject to translational regulation by its 50 UTR, we replaced
the above mentioned luciferase open reading frame (ORF) with
the PRL-3 coding sequence to make another set of eight
corresponding PRL-3 mini-genes (Figure 3E, a0–h0) and then
transfected them respectively into the DLD-1 cell line. By
western blot, we found a minimum of two GC-motifs (Figure 3F,
construct f0) were required to completely suppress exogenous
PRL-3 protein expression. A single copy of the GC-motif (Fig-
ure 3F, construct g0) showed partial suppression of PRL-3
translation compared with complete loss of suppression in
construct h0 that contained no GC-motifs. This suggested that
the GC-motifs were responsible for the regulation of PRL-3
translation in DLD-1 cells. We then transfected the eight PRL-3
mini-genes (Figure 3E, a0–h0) into HCT-116 cells. Consistent
with observations in Figure 3F, a clear increase in PRL-3 level
was observed when the last GC-motif was removed (Fig-
ure 3G, h0 with red circle), which was probably due to the trans-
lation of exogenous PRL-3. The quantitative mini-PRL-3 mRNA
abundance is shown in Figures S1H and S1I, respectively, for
DLD-1 and HCT-116 cells. The rate of translation efficiency of
PRL-3 differs between cell types with DLD-1 showing a higher
rate of repression compared to HCT-116 colon cancer cells.
PCBP1 Binds Specifically to the GC-Rich Motif
To study how the translational repression was rendered by the
6-base GC-motif cis-element, we predicted the secondary
structure of the 50 UTR of human PRL-3 mRNA with or without
the six-base GC-motif by using MFOLD (http://mfold.bioinfo.
rpi.edu/cgi-bin/rna-form1.cgi). There was no difference in
secondary structure with or without the presence of the six-base sequence (data not shown). We therefore anticipated
that a trans-acting factor might act on these six-base GC-
motifs. To explore this possibility, we synthesized two biotin-
conjugated single strand RNA probes mimicking part of the 50
UTR of PRL-3 mRNA: one with the GC-motif (RNA-GC+) and
another without the GC-motif (RNA-GC). Cytoplasmic protein
extract from DLD-1 cells was incubated with either RNA-GC+ or
RNA-GC and then the RNA-protein complexes formed were
affinity pulled-down using streptavidin beads. Eluted proteins
were resolved on a gradient SDS-PAGE gel. A specific protein
band pulled down only by RNA-GC+ is indicated with a red
arrow (Figure 4A). The band was excised for mass spectrometry
analysis and revealed to be PolyC-RNA-binding protein 1
(PCBP1). To validate the specific binding of PCBP1 to the
GC-motif, we incubated purified PCBP1 with biotin-labeled
RNA-GC+ or RNA-GC probes in a RNA gel mobility shift
assay. As shown in Figure 4B, PCBP1 bound only to RNA-
GC+ (but not to RNA-GC) in a dose-dependent manner;
causing a band shift indicated with arrowhead (Figure 4B).
These results show that PCBP1 specifically binds to RNA that
contains the GC-motif.
PCBP1Regulates PRL-3 Protein Levels and AKTActivity
To examine the role of PCBP1 in regulating PRL-3 expression,
we assessed the expression of both proteins in four colon cancer
cell lines. An inverse correlation between PCBP1 and PRL-3
protein expression was observed (Figure 4C). These results
suggest that PCBP1 may be functioning in these cells to repress
PRL-3mRNA translation. Consistently, expression of exogenous
EGFP-PCBP1 in HCT-116 and A2780 human cancer cell
lines reduced their endogenous PRL-3 protein expressions
(Figure 4D, lanes 2 and 4). The downregulation of PRL-3 was
accompanied by the downregulation of the phosphorylated
active form of AKT (pSer473). Conversely, knockdown of endog-
enous PCBP1 in HCT-116 (using shRNA) and in A2780 cells
(using siRNA) results in a robust upregulation of PRL-3 protein
levels as well as an increase in the levels of the active form of
p-AKT (Ser473) (Figure 4E, lanes 2 and 4). The data supports
our previous observation that overexpression of PRL-3
enhances the activity of AKT in DLD-1 cells (Wang et al.,
2007a). Thus, PCBP1 negatively modulates PRL-3 translation
and reduces AKT activity.
PCBP1 Affects the Efficiency of PRL-3 mRNA
Translation
To understand how PCBP1 affects the translation of PRL-3
mRNA, we determined its ribosome occupancy in cells that did
or did not express PCBP1. A representative distribution profile
of the ribosomes is shown (Figure 5A). In HCT-116 parental cells
that express low levels of PCBP1 protein but high levels of
endogenous PRL-3 protein (Figure 4C, lane 2), PRL-3 mRNA
can be found in the heavier polysome fractions (Figure 5B, a:
9–11, red circle), indicating it was highly translated. When
PCBP1 protein was overexpressed in HCT116 cells, PRL-3
mRNA was shifted into lighter polysome fractions (Figure 5B,
b: 6–8, red circle). In agreement with this observation, in DLD-1
cells that have high levels of PCBP1 protein but low levels of
PRL-3 protein (Figure 4C, lane 3), the PRL-3 mRNA was found
in the lighter polysome fractions (Figure 5C, a: 5–8, red circle).Cancer Cell 18, 52–62, July 13, 2010 ª2010 Elsevier Inc. 55
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Figure 3. Identification of Three GC-Motifs, GCCCAG, at the 50 UTR of PRL-3 mRNA
(A) A schematic diagram of human PRL-3 mRNA illustrates a long 50 UTR (855 bases), encoding region (519 bases), and a long 30 UTR (540 bases) (sequences
shown in Figure S1A).
(B) A 2.4 kb genomic fragment (in purple) together with the first exon region corresponding to different 30-deletions of the 50 UTR (in blue) were inserted at the 50 of
the luciferase gene (in light blue) in the pGL3-Basic luciferase reporter vector. Constructs are designated a–h, respectively (primer sequences provided in Supple-
mental Experimental Procedures).
(C and D) Equal amounts of the indicated luciferase reporter plasmid DNA (a–h) were transiently cotransfected with pRL-TK encoding the Renilla luciferase as an
internal normalized control into DLD-1 or HCT-116 cells respectively. Data are the mean ± standard deviation (SD) of three independent experiments; bottom
panels, RT-PCR showed similar mRNA abundance among eight constructs (a–h) in DLD-1 and HCT-116 cells (for quantitative RT-PCR, also see Figures S1B
and S1C).
(E) The luciferase ORF from constructs a–h was replaced with the PRL-3 coding region, the new set of constructs are designated respectively as a0–h0. The posi-
tions of the 50 UTR deletions relative to the start site (+1) of transcription are shown. The start codon ATG is shownwith an arrow, and the coding region of PRL-3 is
shown in red.
(F and G) Equal amounts of the indicated PRL-3 mini-gene plasmid DNAs (a0–h0 ) were transiently cotransfected with pRL-TK into DLD-1 cells or HCT-116 cells.
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Figure 4. Identification of PCPB1 as
a Binding Protein for the GC-Motif in the 50
UTR of PRL-3 mRNA
(A) RNA affinity pull-down assay was used to iden-
tify specific GC-motif binding proteins that were
then resolved on a 9%–16% SDS-PAGE gradient
gel with silver stain. The red arrow indicates
a band that was pulled down by the single
stranded RNA bait RNA-GC+ but not by the RNA
bait RNA-GC.
(B) EMSA of PCPB1 showed that it bound specif-
ically to RNA-GC+, but not to RNA-GC probe
in vitro. Free RNA probes (arrows) and PCPB1-
RNA complex (arrowhead) are indicated. The
amount of PCPB1 protein is indicated on the top
of each lane. All RNA probes are labeled with
biotin.
(C) Immunoblot analysis shows the levels of PRL-3
and PCBP1 protein in four different colon cancer
cell lines, with GAPDH as a loading control.
(D) Overexpression of PCPB1 inhibits PRL-3
expression and reduces phosphorylation of AKT
at pSer473 (lanes 2 and 4). Lanes 1 and 3 repre-
sent HCT-116 and A2780 parental cells.
(E) Knockdown of PCPB1 increases PRL-3
expression and upregulates AKT phosphorylation
(lanes 2 and 4). Lanes 1 and 3 represent HCT-
116 and A2780 parental cells.
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PCBP1 Suppresses PRL-3The data suggest that the low PRL-3 protein levels in DLD-1 cells
are due to translational repression. This level of shift in ribosomal
load would account for the differences in protein level seen in
HCT-116 and DLD-1 cells (Figure 4C). Importantly, knockdown
of PCBP1 in DLD-1 cells resulted in a clear shift of PRL-3
mRNA localization toward heavier polysomal fractions
(Figure 5C, b: 8–11, red circle), suggesting that knockdown of
PCBP1 could release the inhibition of PCBP1 on PRL-3 transla-
tion. To further confirm the role of PCBP1 in the translational
repression of PRL-3, we expressed luciferase reporter
construct g (1-GC-motif; Figure 3B) and construct h (no GC-
motif; Figure 3B) in DLD-1 cells and found that in the presence
of the PCBP1 binding region-GC-motif (construct g, Figure 3B),
the luciferasemRNAwas found in the lighter fractions (Figure 5C,
c: 5–8, red circle), similar to endogenous PRL-3 mRNA
(Figure 5C, a: 5–8, red circle). In contrast, the luciferase mRNA
(construct h, Figure 3B) that had no PCBP1 binding GC-region
was shifted to the heavier polysomal fractions (Figure 5C,
d: 8–11, red circle). These results suggest that the transla-
tion of PRL-3 protein was regulated by PCBP1 binding to its
cognate GC-motif, thus the level of PCBP1 protein can directly
affect the association of PRL-3 mRNA with polyribosomes.
This finding leads us to propose a working model for the action
of PCBP1 in regulating the translation of the PRL-3 mRNA
(Figure 5D).
PCBP1 and PRL-3 Protein Levels Were Inversely
Correlated in Human Cancer Samples
To verify whether our findings in cancer cell lines were of clinical
relevance, we examined 47 human cancer samples (ten stom-Western blot shows the protein levels of PRL-3 and GAPDH; bottom panels, RT
fected into DLD-1 cells or HCT-116 cells (for quantitative RT-PCR; see also Figuachs, ten colon, ten breast, five lung, five brain, five liver, and
two prostate) and found common discordance between PRL-3
mRNA and PRL-3 protein levels (Figure 6A and Figure S2).
More importantly, in agreement with our cell culture data, we
found a strong inverse correlation between PCBP1 and PRL-3
protein levels in the ten stomach tumor samples (Figure 6Ab).
Results from analyzing serial sections of a colon sample by
various methods are presented in Figure 6B. By in situ hybridiza-
tion, a PRL-3 sense probe gave no signal (Figure 6Ba), whereas
an antisense probe detected PRL-3 mRNA in both normal and
cancerous colon epithelia (Figure 6Bb). IHC analysis revealed
that PRL-3 protein was only expressed in cancerous but not
normal epithelia (Figures 6Bc and 6C), whereas PCBP1 protein
was only expressed in normal but not cancerous epithelia
(Figure 6Bd). Similar results were obtained by IHC analysis of
63 lung and 72 colon cancer tissue arrays in that overexpression
of both PRL-3 and PCBP1 was rarely observed in the same
cancer tissues or cells (summarized in Figure 6D). Taken
together, these data demonstrate that PRL-3 and PCBP1 protein
levels showed an inverse correlation in that PCBP1 and PRL-3
proteins are detected predominantly/respectively in normal
and cancerous epithelium of tissue samples.
Overexpression PCBP1 Abrogated Tumor Formation
whereas Knockdown PCBP1 Enhanced Tumorigenesis
To directly examine the function of PCBP1 in tumor progression,
we knocked down endogenous PCBP1 or overexpressed exog-
enous PCBP1 in HCT-116 cells and then injected these cell
pools into the right or left hip areas, respectively, of four nude
mice to compare their ability to form tumors. Knockdown-PCR showed similar mRNA abundance among eight constructs (a0–h0) trans-
res S1H and S1I).
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Figure 5. PCBP1 Causes PRL-3 mRNA to Shift into the Lighter Poly-
somal Fractions
(A) A representative distribution profile of ribosomes from the lightest to the
heaviest fractions in the sucrose gradient. The marked numbers match to
equivalent collected fractions. Fraction 1 represents the top (10%) of the
gradient, fraction 11, the bottom (50%) of the gradient.
(B) As shown in (Ba), a significant amount of PRL-3 mRNA in HCT-116 cells is
associated with the heavy polysomal fractions (9–11, red circle). As shown in
(Bb), overexpression of PCPB1 in HCT-116 cells results in a shift of PRL-3
mRNA to the lighter polysome fractions (6–8, red circle). b-actin mRNA polyso-
mal distribution is unaffected by PCBP1 protein. rRNAs are shown to demon-
strate polysome integrity.
(C) As shown in (Ca), PRL-3 mRNA is associated with the lighter polysomal
fractions in DLD-1 cells (5–8, red circle). As shown in (Cb), Knockdown of
endogenous PCBP1 in DLD-1 cells causes a shift of PRL-3 mRNA localization
toward heavier polysomal fractions (8–11, red circle). As shown in (Cc), The
luciferase construct g (1-GC-motif) mRNA is associated with the lighter poly-
somal fractions (5–8, red circle) in DLD-1 cells. As shown in (Cd), the luciferase
construct h (0-GC-motif) mRNA is predominantly associated with the heavier
polysomal fractions (8–11, red circle) in DLD-1 cells. rRNA and b-actin levels
are shown.
(D) Schematic model depicting how PCBP1 can negatively regulate translation
of PRL-3 mRNA. When PCPB1 protein level is high, it binds to the GC-rich
motifs at the 50 UTR of PRL-3 mRNA to reduce PRL-3 translation efficiency
(upper panel). When PCPB1 protein level is low, the GC-motifs are freed of
PCBP1, resulting in increased PRL-3 translation (lower panel).
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(Figure 7A, left hip), whereas overexpression of exogenous
PCBP1 markedly inhibited tumorigenesis (Figure 7A, right hip).
To make a more quantitative comparison, we repeated the
same experiment with four additional mice. The combined
results from all eight mice showed that the weights of tumors
formed by PCBP1 knocked-down cells were significantly heavier
than the weights of tumors formed by cells overexpressing
PCBP1 (p = 0.0019, paired t test). These results show clearly
that PCBP1 acts as a tumor suppressor in vivo.
DISCUSSION
The PRL-3 phosphatase is becoming important both as
a biomarker for multiple human cancers and as a therapeutic
target for metastatic tumors. Consistent with earlier studies
(Bardelli et al., 2003; Kato et al., 2004; Peng et al., 2004; Wang
et al., 2007b), our analysis confirmed that PRL-3 protein is often
upregulated in human cancers. Accumulating evidence indi-
cates that inhibiting PRL-3 overexpression may reduce cancer
metastasis. Knowledge of how PRL-3 is regulated is important
to understand how PRL-3 spurs cancer progression. Currently,
upstream regulators and downstream targets of PRL-3 are not
well defined. In our current study, we have identified triple six-
base GC-rich cis-elements in the 50 UTR of the PRL-3 mRNA
that are targeted by PCBP1 to mediate translational repression.
The three copies of the GC-motif may serve to triple-check at
translational levels. Binding of PCBP1 to the six-base GC-motifs
resulted in dramatic downregulation of PRL-3 translation as
demonstrated by both a decrease in ribosomal occupancy and
protein levels. We found that overexpression of exogenous
PCBP1 caused marked decrease in the levels of endogenous
PRL-3 protein with a concomitant decrease in AKT activation,
whereas knockdown of endogenous PCBP1 led to upregulation
of PRL-3 protein expression and promoted AKT activation.
These results support our previous data that overexpression of
PRL-3 results in the activation of AKT in DLD-1 cells (Wang
et al., 2007a). AKT mediates several well-described PI3K
responses, including growth, metabolism, and glucose homeo-
stasis (Manning and Cantley, 2007), and activation of AKT is
known to enhance tumorigenesis. Although PRL-3 was previ-
ously shown to downregulate PTEN to influence AKT activation
(Wang et al., 2007a), we did not see obvious changes in PTEN
protein levels in response to the perturbation of PCBP1 levels
here (data not shown), suggesting that the regulation of PTEN
levels is complex. Future experiments are needed to uncover
additional mechanistic aspects in the relationship between
PRL-3 and PTEN. Our data suggest the existence of a
PCBP1 – PRL-3 – AKT signaling pathway. PCBP1 thus functions
to fine-tune PRL-3 levels by regulating the rate of translation, and
keep metastatic genes such as PRL-3 under control.
These data clearly demonstrate a critical role for PCBP1 in
regulating PRL-3 translation and provide mechanistic insight
into how PRL-3 protein expression can be regulated at the trans-
lational level. Expression of PCBP1 does not appear to induce
a complete inhibition of translation, but rather a reduction in its
efficiency. Previous elegant studies have describedPCBP1 func-
tioning to inhibit 80S ribosome assembly (Ostareck et al., 2001;
Ostareck et al., 1997), and it is possible that PCBP1 could
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Figure 6. An Inverse Correlation between
PCBP-1 and PRL-3 Protein Levels in Human
Cancer Samples
(A) As shown in (Aa), RT-PCR shows PCBP1, PRL-
3, andGAPDHmRNAs; in (Ab), western blot shows
PCBP-1, PRL-3, and GAPDH protein levels. An
inverse correlation between PCBP1 and PRL-3
protein levels is observed in eight of ten tumors
(lanes: 1–3 and 6–10).
(B) Detection of PRL-3 mRNA in normal and
cancerous colon tissue by in situ hybridization
using a PRL-3 sense probe as a negative control
(Ba) or a PRL-3 antisense probe (Bb). PRL-3
protein was detected in cancerous but not normal
epithelia (Bc) and PCBP-1 protein was detected in
normal but not cancerous epithelia (Bd) using
immunohistochemistry. The scale bar represents
200 mm.
(C) The section showed that PRL-3 protein was ex-
pressed in cancerous but not normal epithelia.
A red arrowhead indicates the transition area
between cancerous and normal colon tissue. The
scale bar represents 100 mm.
(D) Summary of the expressions of PCBP1 and
PRL-3 protein by IHC on tissue array.
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PCBP1 Suppresses PRL-3function in a similar manner on PRL-3 mRNA. Recently, critical
dose-sensitive effects of PRL-3 expression in both positive and
negative regulation of cell-cycle progression provided insight
into PRL-3’s role in cancer progression, emphasizing the impor-
tance of proper and precise modulation of PRL-3 protein levels
during the cell cycle (Basak et al., 2008). Given such sensitivity
of cells to the levels of PRL-3 protein, together with previous
data on PRL-3 mRNA expression (Saha et al., 2001), we suggest
that PRL-3 is under dual regulatory control at both mRNA and
protein levels to ensure fidelity of its expression.
PCBP1 has been reported to be downregulated in metastatic
cervical cancers (Pillai et al., 2003) and metastatic breast cancer
cells (Thakur et al., 2003). Our evidence that PCBP1 can down-
regulate PRL-3 translation indicates that PCBP1 could be a
tumor suppressor. Consistently, overexpression or knockdown
of PCBP1 in HCT-116 cells led to decreased or increased tumor-
igenesis, respectively, which correlated with PRL-3 levels and
AKT activation. Understanding how the PRL-3 gene is regulated
will help us to develop strategies to block excess PRL-3 expres-
sion or inhibit its activity and thus prevent it from promoting
cancer metastasis. Similar studies on the protein level of p53Cancer Cell 18, 5(Takagi et al., 2005), folate receptor (Sun
and Antony, 1996), cyclooxygenase-2
(Fiori et al., 2005), and Alzheimer’s
disease protease b-site APP-cleaving
enzyme 1 (Lammich et al., 2004) have all
demonstrated the importance of such
translational regulation. We suggest that
our current results will open an avenue
for further study of the biological func-
tions of PCBP1 on other genes.
The inverse correlation of PCBP1
protein levels with PRL-3 protein levels
observed in several types of humancancer suggests that our mechanistic results obtained from
analyzing cancer cell lines are of clinical relevance. Besides
PCBP1-mediated translational suppression, PRL-3 levels can
also be regulated at the mRNA expression level by gene amplifi-
cation (Saha et al., 2001). It seems that multiple mechanisms
may together be responsible for regulating the protein levels
under both physiological and pathological conditions. Accord-
ingly, observed upregulation of PRL-3 proteins in diverse human
cancers may be due to alterations of any of these or any combi-
nation of these various mechanisms. Our results from human
cancer cell lines and diverse human primary cancer samples
indicate that deregulation of PCBP1-mediated translational
suppression may be one of the major mechanisms responsible
for PRL-3 protein overexpression in several human cancers.
EXPERIMENTAL PROCEDURES
Histopathologic Analyses with Immunohistochemistry
Human tissue samples were obtained from the National University Hospital-
National University of Singapore (NUH-NUS) Tissue Repository with approval
of the Institutional Review Board (IRB) of NUH-NUS for research uses. The use
of all human tissue samples including commercial samples were approved2–62, July 13, 2010 ª2010 Elsevier Inc. 59
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Figure 7. Knockdown of Endogenous PCBP1 Enhanced Tumorigenesis whereas Overexpression of Exogenous PCBP1 Abrogated Tumor
Formation
(A) HCT-116 cells in which endogenous PCBP1 was knocked down were injected subcutaneously into the left sides (black arrows) of the hip area of nude mice,
whereas HCT-116 cells that overexpress exogenous PCBP1 were injected into the right sides as indicated with red arrows. The arrows indicate the sites of injec-
tion. The tumor cells were propagated in vivo for 4 weeks.
(B) Xenograft tumors (L1–L4)were derived respectively from the left sides of nudemice 1–4, respectively, whereas xenograft tumors (R3–R4) were derived from the
right sides of nude mice 3 and 4, respectively. Tumors were photographed.
(C) The same experiment was repeated with four additional mice. The graph illustrates the distribution of xenograft tumor weights between two groups.
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PCBP1 Suppresses PRL-3by Institutional Review Board (IRB) of the Institute of Molecular and Cell
Biology. We investigated PRL-3 protein expression on a large collection of
human cancer samples. The majority of the tissues were purchased from
Cybrdi (Rockville, MD; http://cybrdi.com/index.php). These include a major
solid tumor tissue array (CC00-01-006), squamous cell carcinoma (CC00-
01-009), lung carcinoma (CC04-01-003 and CC04-01-006), colon adenocarci-
noma (Grade I III) with normal controls (CC05-01-001), breast carcinoma
(CC08-02-001), and pancreatic carcinoma (Duct adenocarcinoma/islet cell
carcinoma/mucinous carcinoma) with normal controls (CC14-01-001). Human
low density prostate tissue array (TS42081004) was purchased from
InnoGenex (San Ramon, CA). In addition, some formalin-fixed and paraffin-
embedded surgical specimens of primary multiple cancer samples were
collected from the archives of the pathology department of the Henan Medical
Hospital and National University Hospital in Singapore. We used Dako
EnVision Systems K 1395 (Dako, Carpinteria, CA) to perform IHC analysis
(Supplemental Experimental Procedures).
Cancer Cell Lines and Cell Culture
Colon cancer cell lines include the following: HCT-15 (CCL-225), HT-29
(HTB-38), HCT-116 (CCL-247), DLD-1 (CCL-221), LS411N (CRL-2159), LoVo
(CCL-229), SW620 (CCL-227), CT-26 (CRL-2638), Colo205 (CCL-222), breast
cancer cell lines: SkBr3 (HTB-30), MCF-7 (HTB-22), MCF-10A (CRL-10317,
immortalized cell line), and a stomach cancer cell line: SNU-1(CRL-5971)
were obtained from ATCC (Manassas, Virginia). Cells were maintained in the
appropriate media with 10% heat-inactivated fetal bovine serum and 1%
antibiotics at 37C with 5% CO2.
Northern Blot Analysis and Reverse Transcription-PCR
Total RNAs were isolated with the RNeasy mini kit (QIAGEN) and separated on
a 1.5% formaldehyde-denaturing agarose gel before being transferred onto
nitrocellulose membranes. Northern blotting was carried out using DIG-labeled
antisense probes corresponding to nucleotides 840–1210 of PRL-3 (accession
number NM032611), nucleotides 741–989 of b-actin (accession number
X03672), and nucleotides 550–1537 of luciferase (accession number
NM001101.3). The bound probes were visualized by incubation with alkaline
phosphatase-conjugated anti-DIG antibodies, washed, and exposed to film
with CDP-Star substrate (Roche Diagnostics). For amplification of the human
PRL-3 cDNA fragment (474 bp) andGAPDH fragment (450 bp) with PCR primers
described in theSupplementalExperimentalProcedures, thePCRproductswere60 Cancer Cell 18, 52–62, July 13, 2010 ª2010 Elsevier Inc.analyzed with a 1.3% agarose gel (Figure 3), scanned with GS-800 Calibrated
Densitometer (BioRad), and theband imageswere further analyzedwithQuantity
One Software (BioRad). Quantitative RT-PCR was shown in Figure S1.
Immunoblotting
Cells were harvested and lysed in cell lysis buffer (50 mM Tris-HCl [pH 7.4],
250 mM NaCl, 0.1% NP-40, 5 mM EDTA, 2 mg/ml leupeptin, 2 mg/ml aprotinin,
4 mM Prefabloc SC, and protein inhibitor cocktail). The cell lysates were sub-
jected to SDS-PAGE. PRL-3monoclonal antibodies (clones 223 and 318) were
used. The detailed immunoblotting procedures had been described previously
(Li et al., 2005). PCPB1 and GAPDH antibodies were obtained from Santa
Cruz; phospho-AKT (Ser473) and total AKT antibodies were purchased from
Cell Signaling Technology.
Plasmid Constructions
For obtaining the promoter region of human PRL-3, genomic DNA was
extracted from DLD-1 cells. Primers 50-GGCCGACGCGTGGCAGGGCAGA
GCCACATAG-30 with a Mlu I restriction site and 50- CGGCGCTCGAGGG
CGCCTCCCGACGGGCCC-30 with an Xho I site were used to amplify the
3.3 Kb genomic fragment preceding the translation initiation site ATG of the
PRL-3 coding sequence. This 3.3 Kb fragment contains two regions: the first
corresponding to the upstream promoter sequences (2.4 kb), and the second
corresponding to the exon (855 bp) contains the 50UTR of the PRL-3 mRNA.
The 3.3 Kb fragment was doubly digested with MluI and XhoI and subcloned
into the pGL3-Basic vector (Promega), which is located upstream of the firefly
luciferase (reporter gene) to form pGLR3-luciferase (construct 2456–+855).
Primers (Supplemental Experimental Procedures) were used to generate
constructs (a–h, Figure 3B). Furthermore, forward primer: 50-GGCCATCC
ATGGCTCGGATGAACCGCCCGGCCCCGG-30 (with NcoI site underlined)
and reverse primer: 50-GGCCATTCTAGACTACATAACGCAGCACCGGGTC
TTGTG-30 (with Xba I site underlined) were used to obtain a PCR fragment
for PRL-3 coding region, which was then used to replace the luciferase
reporter gene as constructs a0–h0 (Figure 3E).
RNA Affinity Binding Proteins and Mass Spectrometry Analysis
Two different HPLC-grade single-stranded PRL-3 RNA probes corresponding
to positions +35 to +65 of 50 UTRwere synthesized, namely RNA-GC+with the
GC-motif at position +49 to +55: 50-GAGUGGGCCACGGGGCCCAGCCC
UAAGCAC-biotin-30, and RNA-GC- without the GC-motif: 50-GAGUGGGCCA
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PCBP1 Suppresses PRL-3CGGGCCCUAAGCAC-Biotin-30 (Sigma-Proligo). Cytoplasmic cell extracts
were isolated from 1 3 107 DLD-1 cells and RNA affinity capture was subse-
quently carried out with streptavidin magnetic MicroBeads (Miltenyi Biotec)
as described previously (Takagi et al., 2005). Elutes were separated on a
9%–16% gradient SDS-PAGE and visualized by silver staining. Selected
bands that specifically associated with RNA-GC+ (but not RNA-GC-) were
excised for LC-MS analysis.
RNA-Electrophoretic Mobility Shift Assays
The encoding region of PCBP 1 was amplified from a cDNA library of DLD-1
cells by RT-PCR, using the primers: 50-GGATCCCCGGGAATGGATGC
CGGTGTGACTGAAAGTGG-30 and 50-CCGGTAAGCTTCTAGCTGCACCC
CATGCCCTTCTC-30 (with XmaI and HindIII restriction sites). The PCR frag-
ment was doubly digested with XmaI and HindIII and inserted into the respec-
tive sites of pGEX-KG vector to make GST-PCPB1 fusion protein. The insert
was confirmed to be free of mutations by sequencing. The purified GST-
PCBP 1 fusion protein was cleaved by thrombin (Sigma) to remove the GST
tag. RNA-GC+ and RNA-GC were respectively incubated with the indicated
amount of purified PCBP1 in the presence of excess yeast tRNA at 30C for
20min. The binding complexes were resolved on a 15% native polyacrylamide
gel and then transferred to nitrocellulose membrane (Amersham). The
biotin-containing bands were visualized by incubation with streptavidin-HRP
conjugates for 1 hr, then washed three times and exposed to film with HRP
luminescent substrates (Pierce).
Knockdown or Overexpression of PCBP 1
A2780 cells were transfected with either siRNA targeting human PCPB1 (sc-
43843; Santa Cruz Biotechnology) or mock siRNA using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. We also constructed
2 HuSH29-mer shRNAs (50-TCACCGAGTGTGTCAAGCAGATTTGCCTG-30
and 50-TGGTAGGCAGGTTACTATCACTGGCTCTG-30) in p-GFP-V-RS vector
(TG310588, OriGene Technologies, Rockville, MD) to stably knockdown
PCPB1 in DLD-1 and HCT-116 cells. For overexpression studies, HCT-116
or A2780 cells were transfected with pEGFP-PCBP1 plasmids, in which
PCBP1 is fused to the C-terminus of EGFP protein in a pEGFP-C1 vector
(Clonetech). Twenty-four hours after seeding, the cells were harvested and
lysed in cell lysis buffer (as noted above) for western blot analysis to examine
the expression levels of various proteins.
Measuring the Distribution of mRNA in Ribosome Fractions
For polyribosome isolation (Takagi et al., 2005), cells were incubated with
90mg/mlcycloheximide (Sigma) for10min followedbytrypsinizationandharvest.
Twenty million cells were resuspended in RSB (20mM Tris-HCl [pH 7.4], 20 mM
NaCl, 30mMMgCl2, RNasin, 100 mg/mlHeparin, and 5 mg/ml cycloheximide). An
equal volume of lysis buffer (1.2% Triton X-100, 1.2% deoxycholate) was added
and and then incubated on ice for 5min. The nuclei and cell debriswere removed
by centrifugation for 3 min at 12,000 rpm. The supernatant was then diluted with
an equal volumeof dilution buffer (25mMTris-HCl [pH 7.4], 25mMNaCl, 25mM
MgCl2, 0.05%Triton X-100, and 500 mg/ml heparin) and 400 ml of the extract was
loaded onto 11.5 ml linear 10% to 50% sucrose gradients and centrifuged at
36,000 rpm for 2 hr in a SW41 rotor (Beckman). Twelve (1 ml each) fractions
were collected with the BioComp piston gradient fractionator linked to an EM-1
UV Monitor (BioRad). The fractions were incubated in 1% SDS and proteinase
K at 42C for 30min. RNAwas purifiedbyPhenolChloroformextraction followed
by ethanol precipitation. Equal volumes of RNA from each fraction were loaded
onto a formaldehyde-denaturing agarose gel for northern blot analysis.
Extracting Total Proteins fromFresh-FrozenHumanMultipleCancer
Samples
Forty-seven multiple human tumor samples were obtained from NUH-NUS
(National University of Singapore) Tissue Repository. Small, fresh tumor
samples were homogenized and resuspended in lysis buffer (50 mM Tris [pH
7.4], 150 mM NaCl, 1% NP-40, 1 mM EDTA, 2 mg/ml leupeptin, 2 mg aprotinin,
4 mM Prefabloc SC, and protease inhibitor cocktail) for 15 min at 4C. The
supernatant was collected and respun at 55,000 rpm for 40 min at 4C with
a TLA100.2 rotor (Beckman). Each sample was loaded (40 mg/sample) on a
15% gel for SDS-PAGE analysis.In Situ Hybridization on Formalin-Fixed and Paraffin-Embedded
Surgical Specimens to Detect PRL-3 mRNA Expression
An RT-PCR fragment corresponding to the human PRL-3mRNA coding region
was cloned into EcoR1 and BamH1 sites of the pBluescriptII KS/SK (+) phag-
emid. For in situ hybridization, the plasmid was cut with BamH1 and the T3
promoter was used to transcribe the PRL-3 sense probe. Alternatively, the
plasmid was cut with EcoR1 and the T7 promoter was used for transcribing
the PRL-3 antisense probe. We used a DIG RNA Labeling Kit (SP6/T7) to label
the RNAs with digoxigenin-UTP by in vitro transcription with the T7 RNA poly-
merase (Cat. No. 11-175-025-910, Roche) or T3 RNA polymerase (Part
9PIP208, Promega). The protocols were followed according to the manufac-
turer’s instructions.
Tumorigenicity Assays in Mice for Xenograft Tumor Study
One million HCT-116 cells in which PCBP1 was knocked down or overex-
pressed were injected respectively into the left (L, n = 8) or right (R, n = 8)
side of the hip areas of 8-week-old nude mice (Jackson Labs) to examine
the tumorigenicity of the cells in vivo. After 4 weeks, the sizes of the tumor
were monitored and photographed. Prism 4 graphing software (GraphPad
Software) and the paired t test were used for statistic analysis and presenta-
tion. All animal studies were approved by the Institutional Animal Care and
Use Committee (IACUC) and were carried out under the policies of Institute
of Molecular and Cell Biology’s Review Board (IRB), Singapore.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2010.04.028.
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